Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.

Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ; Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO)., Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Górski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H; Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE)., Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H; German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC)., Spurdle AB, Chen X, Waddell N, Cloonan N; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab)., Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)..

Am J Hum Genet. 2007 Dec;81(6):1186-200.

2.

A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration.

Pariente N, Morizono K, Virk MS, Petrigliano FA, Reiter RE, Lieberman JR, Chen IS.

Mol Ther. 2007 Nov;15(11):1973-81.

PMID:
17653099
3.

Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation.

Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, Lazar AJ, Yu D, Pollock RE, Lev D.

Mol Cancer Ther. 2007 May;6(5):1650-60.

4.

Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.

Fujiwara T, Urata Y, Tanaka N.

Curr Cancer Drug Targets. 2007 Mar;7(2):191-201. Review.

PMID:
17346111
5.

Oncolytic viruses driven by tumor-specific promoters.

Hardcastle J, Kurozumi K, Chiocca EA, Kaur B.

Curr Cancer Drug Targets. 2007 Mar;7(2):181-9. Review.

PMID:
17346110
6.

In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus.

Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F, Teraishi F, Kyo S, Mizuguchi H, Hashimoto Y, Urata Y, Tanaka N, Fujiwara T.

Nat Med. 2006 Oct;12(10):1213-9.

PMID:
17013385
7.

Characterisation of the promoter region of the human DNA-repair gene Rad51.

Hasselbach L, Haase S, Fischer D, Kolberg HC, Stürzbecher HW.

Eur J Gynaecol Oncol. 2005;26(6):589-98. Review.

PMID:
16398215
8.

Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.

Bilsland AE, Fletcher-Monaghan A, Keith WN.

Neoplasia. 2005 Nov;7(11):1020-9.

9.

p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene.

Arias-Lopez C, Lazaro-Trueba I, Kerr P, Lord CJ, Dexter T, Iravani M, Ashworth A, Silva A.

EMBO Rep. 2006 Feb;7(2):219-24.

10.

Cancer-specific gene therapy.

Lo HW, Day CP, Hung MC.

Adv Genet. 2005;54:235-55. Review.

PMID:
16096014
11.

High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients.

Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, Fischer D, Kolberg HC, Kruger S, Stuerzbecher HW.

Br J Cancer. 2005 Jul 11;93(1):137-43.

12.

The RAD51 gene family, genetic instability and cancer.

Thacker J.

Cancer Lett. 2005 Mar 10;219(2):125-35. Review.

PMID:
15723711
13.

RAD51, genomic stability, and tumorigenesis.

Richardson C.

Cancer Lett. 2005 Feb 10;218(2):127-39. Review.

PMID:
15670890
14.

The life and death of DNA-PK.

Collis SJ, DeWeese TL, Jeggo PA, Parker AR.

Oncogene. 2005 Feb 3;24(6):949-61. Review.

PMID:
15592499
15.

Cancer-specific activation of the survivin promoter and its potential use in gene therapy.

Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC.

Cancer Gene Ther. 2004 Nov;11(11):740-7.

PMID:
15359286
16.

Midkine promoter-driven suicide gene expression and -mediated adenovirus replication produced cytotoxic effects to immortalised and tumour cells.

Yu L, Hamada K, Namba M, Kadomatsu K, Muramatsu T, Matsubara S, Tagawa M.

Eur J Cancer. 2004 Jul;40(11):1787-94.

PMID:
15251170
17.

Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability.

Richardson C, Stark JM, Ommundsen M, Jasin M.

Oncogene. 2004 Jan 15;23(2):546-53.

PMID:
14724582
18.

Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.

Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, Tofilon PJ.

Cancer Res. 2003 Nov 1;63(21):7377-83.

19.

Transcriptionally targeted gene therapy to detect and treat cancer.

Wu L, Johnson M, Sato M.

Trends Mol Med. 2003 Oct;9(10):421-9. Review.

20.

Telomerase promoter-driven cancer gene therapy.

Gu J, Fang B.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S64-70. Review.

PMID:
14508082
Items per page

Supplemental Content

Support Center